Earlier in November, the American College of Rheumatology held its 71st annual scientific meeting. Among the many research studies discussed and presented at the meeting, several made the news recently which may offer some hope or comfort to RA sufferers, especially those in the early stages of the disease or who have seropositive RA.
First, scientists at the University of California, San Diego found that anti-TNF inhibitor therapy may provide lasting benefits for up to a year for patients,...

